Pfizer’s breast cancer-fighter Ibrance posts stellar second-line survival data

Carly Helfand Last month, Pfizer announced it had cut short its PALOMA-3 trial thanks to impressive second-line data for new cancer-fighter Ibrance. And now, industry-watchers have ...

Clovis boasts promising ovarian cancer responses for AstraZeneca rival rucaparib

John Carroll Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on ...

Adding Opdivo to Yervoy ups melanoma treatment efficacy–but it ups rate of serious side effects, too

Carly Helfand The data on Bristol-Myers Squibb's hot new immunotherapy Opdivo kept rolling out Sunday at ASCO, showing that combining the drug with fellow Bristol cancer-fighter ...

Genentech’s PD-L1 breakthrough star ‘atezo’ positioned to vault ahead on cancer

John Carroll Behind the headlines here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging ...

New standout Imbruvica data bode well for market expansion in CLL

Carly Helfand Johnson & Johnson and AbbVie's Imbruvica has already shown in one Phase III study that it can extend progression-free survival in patients with previously treated ...

FDA demands new warnings on dermal fillers from Actavis, Galderma

Carly Helfand Dermal fillers are meant to minimize the appearance of wrinkles and give the face a smoother, fuller appearance. But they may also have some nasty consequences if injected ...

UPDATED: Bristol-Myers dominates–and disappoints–at ASCO immuno-oncology debut

John Carroll Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of ASCO with a bang, rolling out a slate of new studies spotlighting ...

J&J sets up shop at Karolinska Institutet; Lilly, Zealand scrap R&D pact; Mapi raises $10M

Nick Paul Taylor In this week's EuroBiotech Report, Johnson & Johnson added another outpost to its burgeoning network of startup-scouting units. The J&J-Karolinska Institutet ...

How well paid are pharma execs? Best in healthcare, survey shows

Tracy Staton How does pharma executive pay compare with the rest of healthcare? Forbes columnist Dan Munro decided to find out–and the answer is that drugmakers pay their top ...

Bavarian Nordic quashes talk of interest in a Big Pharma buyout

Nick Paul Taylor Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some ...

As Bayer preps for its slim-down, a restructuring looms–but jobs are safe, CEO says

Carly Helfand As Bayer moves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's ...

Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline

Tracy Staton Get ready for a showdown in the irritable bowel syndrome market. FiercePharma News
Page 1 of 512345
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS